ATE142501T1 - Verwendung von 1-(beta-d-arabinofuranosyl)-5- propynyluracil zur senkung des serumcholesterins - Google Patents

Verwendung von 1-(beta-d-arabinofuranosyl)-5- propynyluracil zur senkung des serumcholesterins

Info

Publication number
ATE142501T1
ATE142501T1 AT92910638T AT92910638T ATE142501T1 AT E142501 T1 ATE142501 T1 AT E142501T1 AT 92910638 T AT92910638 T AT 92910638T AT 92910638 T AT92910638 T AT 92910638T AT E142501 T1 ATE142501 T1 AT E142501T1
Authority
AT
Austria
Prior art keywords
pct
propynyluracil
arabinofuranosyl
beta
serum cholesterol
Prior art date
Application number
AT92910638T
Other languages
English (en)
Inventor
Richard Wilson Peck
John Posner
Kenneth Powell
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE142501T1 publication Critical patent/ATE142501T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT92910638T 1991-05-30 1992-05-29 Verwendung von 1-(beta-d-arabinofuranosyl)-5- propynyluracil zur senkung des serumcholesterins ATE142501T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111580A GB9111580D0 (en) 1991-05-30 1991-05-30 Nucleoside derivative

Publications (1)

Publication Number Publication Date
ATE142501T1 true ATE142501T1 (de) 1996-09-15

Family

ID=10695778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92910638T ATE142501T1 (de) 1991-05-30 1992-05-29 Verwendung von 1-(beta-d-arabinofuranosyl)-5- propynyluracil zur senkung des serumcholesterins

Country Status (14)

Country Link
US (1) US5432166A (de)
EP (1) EP0542952B1 (de)
JP (1) JPH06500129A (de)
AT (1) ATE142501T1 (de)
AU (1) AU657756B2 (de)
CA (1) CA2088264A1 (de)
DE (1) DE69213660D1 (de)
GB (1) GB9111580D0 (de)
HU (1) HUT63767A (de)
IE (1) IE921731A1 (de)
IL (1) IL102058A (de)
MX (1) MX9202595A (de)
WO (1) WO1992021352A1 (de)
ZA (1) ZA923962B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2244328A1 (de) * 1972-09-09 1974-03-21 Boehringer Mannheim Gmbh Neue n(6)-disubstituierte adenosinderivate und verfahren zur herstellung derselben
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
IT1196261B (it) * 1984-09-20 1988-11-16 Pierrel Spa Derivati nucleosidici e purinici 8-sostituiti
US5063233A (en) * 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
GB8629892D0 (en) * 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
HU198950B (en) * 1986-12-15 1989-12-28 Sandoz Ag Process for producing new furanuronic acid derivatives and pharmaceutical compositions comprising such compounds
EP0277917A3 (de) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Bestimmte Derivate von Adenosin-5'-carboxamid
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5028596A (en) * 1987-12-14 1991-07-02 Burroughs Wellcome Co. 1-(β-D-arabinofuranosyl)-5-propynyluracil for treatment of VZV infections
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
AU3820989A (en) * 1988-08-02 1990-02-08 Ciba-Geigy Ag 7-amino-3-beta-d-ribofuranosyl-3h-imidazo(4,5-b) pyridin-5-amine derivatives
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH03287537A (ja) * 1990-03-31 1991-12-18 Yamasa Shoyu Co Ltd 抗動脈硬化症剤
FR2665362B1 (fr) * 1990-08-03 1994-12-09 Cepbepe Substance contenant, comme principe actif, une adenosine substitutee en n6 et son application.

Also Published As

Publication number Publication date
AU657756B2 (en) 1995-03-23
IL102058A (en) 1996-07-23
JPH06500129A (ja) 1994-01-06
WO1992021352A1 (en) 1992-12-10
IE921731A1 (en) 1992-12-02
EP0542952A1 (de) 1993-05-26
GB9111580D0 (en) 1991-07-24
CA2088264A1 (en) 1992-12-01
HU9300243D0 (en) 1993-04-28
EP0542952B1 (de) 1996-09-11
MX9202595A (es) 1992-11-01
DE69213660D1 (de) 1996-10-17
HUT63767A (en) 1993-10-28
ZA923962B (en) 1993-11-29
IL102058A0 (en) 1992-12-30
US5432166A (en) 1995-07-11
AU1767392A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
DE69814394D1 (de) Verwendung von levobupivacain
PT831882E (pt) Composicoes de segmentos de fibra de colagenio reconstituido e metodos de preparacao das mesmas
FI883653L (fi) Mikrobeja tappava mikroemulsio
ES2150492T3 (es) Utilizacion de un material poroso a base de carbonato de calcio como soporte para un factor de crecimiento en la preparacion de un implante.
ATA53492A (de) Verwendung von ciclosporin zur pulmonalen verabreichung
IS2118B (is) Aðferðir til að kalla fram T-eitilfrumu þol í ígræddum vef eða líffæri
ATE288273T1 (de) Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
SE9604793L (sv) Nya Kristallmodifikationer
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69625696D1 (de) Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE169638T1 (de) Analoge des menschlichen interleukin-8.
BR9608100A (pt) Pirazolo[1,5a] pirimidina processos para a sua preparação e para o controle e fungos nocivos e pragas composição e utilização dos compostos
ATE240730T1 (de) Verwendung von levobupivacaine in gesichtschirugie
DE59507755D1 (de) Dipeptidische p-amidinobenzylamide mit n-terminalen sulfonyl- bzw. aminosulfonylresten
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69811248D1 (de) Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe
ATE142501T1 (de) Verwendung von 1-(beta-d-arabinofuranosyl)-5- propynyluracil zur senkung des serumcholesterins
DE69328193D1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
DE69330680D1 (de) Verwendung von 17 Alpha - Dihydroequilenin zur Senkung des Cholesterinspiegels
IL106237A0 (en) Piperidyl amides,sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
NO925048L (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
DE3778158D1 (de) Inhibitoren von esterase produzierenden mikroorganismen zur hauptverwendung in deodorants.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties